Deutsche Bank Starts Pacific Biosciences of California (PACB) at Buy; Valuation Appears Attractive
Tweet Send to a Friend
Deutsche Bank initiates coverage on Pacific Biosciences of California (NASDAQ: PACB) with a Buy. PT $18.
Deutsche analyst says, "PACB ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Deutsche analyst says, "PACB ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
